64th ASH Annual Meeting and Exposition: 802. Chemical Biology and Experimental Therapeutics: Poster II

Symposia: Chemical Biology and Experimental Therapeutics Oral and Poster Abstracts
Poster

Hall D (Ernest N. Morial Convention Center)

DHODH: A Promising New Therapeutic Target in Pediatric T-ALL

Amy N Sexauer, MD, PhD¹, Gabriela Alexe, PhD¹^*, Varsha Gandhi, PhD², Kimberly Stegmaier, MD¹ and David Sykes, MD, PhD³

¹Dana-Farber Cancer Institute, Boston, MA
²MD Anderson, Houston, TX
³Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA

3472

Discovery of HZ-L105, a Next Generation of Bcl-2 Inhibitor, Overcomes Bcl-2 Mutation and Exhibits Superior Antitumor Activity

Xinguo Liu, PhD¹^*, Yang Lou²^*, Yizhe Wu¹^*, Mingbo Su²^*, Anhui Gao²^*, Jinglai Huang¹^*, Haiyan Yang, PhD³, Li Zhong²^* and Xinglu Zhou¹^*

¹Hangzhou HealZen Therapeutics Co., Ltd., Hangzhou, China
²Biopolar Hongye (Nantong) Pharmaceutical Co., Ltd., Nantong, China
³Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China

3473

DIACC2010, Sole-in-Class Selective Inhibitor of Kinesin KIF20A, Has Potent Preclinical Efficacy in Acute Myeloid Leukemia

Sylvain Garciaz, MD PHD¹^*, Yves Collette, PhD^1,2^*, Remy Castellano, PhD^1,2^*, Michel Aurrand-Lions, PhD¹^*, Helene Sicard, PhD³^*, Laetitia Jentreau³^*, Norbert Vey, MD⁴ and Cecile Bougeret, PhD³^*

¹Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France; Centre National de la Recherche Scientifique, UMR7258, Marseille, France; Centre de Recherche en Cancérologie de Marseille, INSERM U1068, Marseille, France, Marseille, France
²TrGET Platform, CRCM, Marseille, France
³R&D, Diaccurate SA, Paris, France
⁴Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS UMR7258, Marseille, France

3474

AT56 Exerts Anti-Tumor Effects in Peripheral T Cell Lymphoma By Regulating HMOX1-Mediated Ferroptosis

Shunfeng Hu, PhD^1,2^*, Yiqing Cai¹^*, Tiange Lu¹^*, Juanjuan Shang¹^*, Mengfei Ding¹^*, Xiangxiang Zhou, PhD^1,2^* and Xin Wang^1,2

¹Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China
²Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

3475

Amplifying Sting Activation By Bio-Inspired Nanomedicine for Targeted Acute Myeloid Leukemia Chemo- and Immunotherapy

Xiaoqi Wang, MD¹^*, Ruihao Huang¹^*, Wei Wu¹^*, Jingkang Xiong¹^*, Qin Wen, MD¹^*, Yunjing Zeng¹^*, Ting Chen¹^*, Jiali Li¹^*, Cheng Zhang, MD, PhD¹^*, Jiang F. Zhong, PhD²^*, Shijie Yang, PhD¹^* and Xi Zhang, MD, PhD¹^*

¹Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical University, Chongqing, China
²Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA

3476

HCK Inhibition Displays Antineoplastic Activity on Acute Leukemia and Promotes Immune Regulation of the Bone Marrow Tumor Microenvironment

Fernanda Marconi Roversi, PhD¹^*, Maura Lima Pereira Bueno, undergraduate¹^*, Audrey Basso, M.Sc.²^*, Adriana Silva Santos Duarte, Ph.D.¹^*, Juliete A.F. Silva, Ph.D.³^* and Sara T Olalla Saad, MD, Ph.D.⁴

¹Hematology and Transfusion Medicine Center- University of Campinas/Hemocentro-UNICAMP, Campinas, São Paulo, Brazil
²Hematology and Hemotherapy Center, University of Campinas, Campinas, Brazil
³Department of Surgery Division of Transplantation, Emory University, Atlanta, Georgia, United State, Atlanta, GA
⁴Hematology and Transfusion Medicine Center-University of Campinas/Hemocentro-UNICAMP,, UNICAMP, Campinas, Brazil

3477

In Vitro and In Vivo Studies Support GFH009, a Selective CDK9 Inhibitor, As a Potential Treatment for Hematologic Cancers

Fusheng Zhou¹^*, Lili Tang¹^*, Siyuan Le¹^*, Mei Ge¹^*, Dragan Cicic, MD², Fubo Xie¹^*, Jinmin Ren¹^*, Jiong Lan¹^* and Qiang Lu¹^*

¹GenFleet Therapeutics, Shanghai, China
²SELLAS Life Sciences Group, Inc., New York, NY

3478

Pre-Clinical Development of a First in Class Half-Life Extended T Cell Engager Targeting ROR-1

David Granger, PhD¹^*, Patricia Henne, PhD²^*, Annalisa Baccaro³^*, Dinusha Fernando⁴^*, Jasmine Gore⁴^*, Ephraim Gbajumo⁴^*, Vincent Muczynski, PhD^5,6^*, Mittal Shah, PhD⁵^*, Kieran O'Donovan, PhD⁴^*, Kerry Chester, PhD^4,7^* and Amit C. Nathwani, MD, PhD^4,8

¹NovalGen Ltd, London, GBR
²NovalGen Ltd, Ruislip, London, ENG, GBR
³NovalGen Ltd, London, ENG, GBR
⁴NovalGen Ltd, London, United Kingdom
⁵NovalGen Ltd, London, ENG, United Kingdom
⁶Cancer Institute, University College London, London, United Kingdom
⁷UCL Cancer Institute, London, United Kingdom
⁸Department of Haematology, Cancer Institute, University College London, London, ENG, United Kingdom

3479

Synergistic Anti-Tumor Effect on Novel Combination of Selinexor with Azacitidine in AML By Targeting XPO1/eIF4E/C-MYC Signaling

Huideng Long¹^*, Chunhua Song, MD, PhD^2,3 and Zheng Ge, MD, PhD¹

¹Department of Hematology, Zhongda Hospital, School of Medicine, Institute of Hematology, Southeast University, Nanjing, China
²Hershey Medical Center, Pennsylvania State University Medical College, Hershey, PA
³Division of Hematology, The Ohio State University Wexner Medical Center, the James Cancer Hospital, Columbus

3480

Multiplex Drug Screening Identifies a Novel Therapeutic Backbone for the Treatment of Acute Myeloid Leukaemia

Lauren V Cairns, PhD, BSc¹^*, Kathryn Clarke, PhD²^*, Mark Catherwood, PhD²^* and Ken I Mills, BSc, PhD, FRCPath³

¹Queen's University Belfast, Belfast, NI, United Kingdom
²Haematology Department, Belfast City Hospital, Belfast, United Kingdom
³Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom

3481

Nanoliposomal C6-Ceramide Exhibits Synergistic Anti-Cancer Activity with a Small Molecule Agonist of PP2A in Chronic Lymphocytic Leukemia

Kallesh D. Jayappa, DVM, PhD¹^*, Luke R. Vass, BSc¹^*, Caroline Farrington, PhD²^*, Anuradha Illendula, PhD^1,3^*, Susan Walker, BSc, MSc, CChem¹^*, Michael E. Williams, MD^4,5^*, Craig A. Portell, MD^6,7, Todd Fox, PhD^1,4^*, Goutham Narla, MD, PhD²^* and Mark Kester, PhD^1,3,4^*

¹Department of Pharmacology, University of Virginia School of Medicine, Charlottesville, VA
²Department of Medicine, University of Michigan, Ann Arbor, MI
³NanoStar, Charlottesville, VA
⁴UVA Comprehensive Cancer Center, University of Virginia, Charlottesville, VA
⁵Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA
⁶Comprehensive Cancer Center, University of Virginia, Charlottesville, VA
⁷Division of Hematology and Oncology, Department of Medicine, University of Virginia, Charlottesville, VA

3482

HZ-R061, a Selective STAT3 Degrader with Activity in Preclinical Model of Hematologic Malignances

Yizhe Wu¹^*, Xinguo Liu, PhD¹^*, Xinxin Jin¹^*, Jiangfeng Xie¹^*, Haiyan Yang, PhD² and Xinglu Zhou¹^*

¹Hangzhou HealZen Therapeutics Co., Ltd., Hangzhou, China
²Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China

3483

The Marine Product Elatol Is a Novel Inhibitor of Mitochondrial Translation Triggering the Integrated Stress Response and Apoptosis in Leukemia and Lymphoma Cells

Tyler A. Cunningham, BS¹^*, Priyanka Maiti, PhD²^*, Paola Manara, BS, MS¹^*, Vivek Singh, PhD^3,4^*, Nigel Beaton, PhD⁵^*, Alexey Amunts, PhD^4,6^*, Flavia Fontanesi, PhD²^*, Antonio Barrientos, PhD²^* and Jonathan H. Schatz, MD¹

¹University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL
²Department of Neurology, University of Miami Miller School of Medicine, Miami, FL
³Department of Biochemistry and Biophysics, Stockholm University, Solna, Sweden
⁴Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
⁵Biognosys, Schlieren, Switzerland
⁶Department of Biochemistry and Biophysics, Science for Life Laboratory, Stockholm University, Solna, Sweden

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH